Skip to main content
. 2017 Nov 14;2017:5929234. doi: 10.1155/2017/5929234

Figure 1.

Figure 1

A diagram summarizing criteria for decision making of go or no-go for each step at discovery and preclinical phases of AL development. The right column is set of criteria during each step (IC50 is concentration that inhibits cell growth by 50%; MTD is maximum tolerated dose; NOAEL is no observed adverse effect level; MRSD is maximum recommended starting dose).